866-997-4948(US-Canada Toll Free)

Neuroblastoma - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Oncology

No. of Pages : 235 Pages

Neuroblastoma - Pipeline Review, H1 2014

Summary

Global Markets Directs, Neuroblastoma - Pipeline Review, H1 2014, provides an overview of the Neuroblastomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Neuroblastoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Neuroblastoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Neuroblastoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Neuroblastoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Neuroblastoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Neuroblastoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Neuroblastoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Neuroblastoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Neuroblastoma Overview 9
Therapeutics Development 10
Pipeline Products for Neuroblastoma - Overview 10
Pipeline Products for Neuroblastoma - Comparative Analysis 11
Neuroblastoma - Therapeutics under Development by Companies 12
Neuroblastoma - Therapeutics under Investigation by Universities/Institutes 16
Neuroblastoma - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Unknown Stage Products 22
Neuroblastoma - Products under Development by Companies 23
Neuroblastoma - Products under Investigation by Universities/Institutes 26
Neuroblastoma - Companies Involved in Therapeutics Development 27
United Therapeutics Corporation 27
Shionogi & Co., Ltd. 28
GlaxoSmithKline plc 29
Gamida Cell Ltd. 30
BioLineRx, Ltd. 31
Novartis AG 32
Chugai Pharmaceutical Co., Ltd. 33
Teva Pharmaceutical Industries Limited 34
Progenics Pharmaceuticals, Inc. 35
Celgene Corporation 36
AEterna Zentaris Inc. 37
Lixte Biotechnology Holdings, Inc. 38
Lorus Therapeutics Inc. 39
Novogen Limited 40
Threshold Pharmaceuticals, Inc. 41
Sareum Holdings plc 42
MabVax Therapeutics, Inc. 43
Bionucleon Srl 44
CerRx, Inc. 45
Merrimack Pharmaceuticals, Inc. 46
Neotropix, Inc. 47
APEIRON Biologics AG 48
Xcovery, Inc. 49
Sutro Biopharma, Inc. 50
Incuron, LLC 51
Errant Gene Therapeutics, LLC 52
DEKK-TEC, Inc. 53
Bexion Pharmaceuticals, LLC. 54
Cancer Prevention Pharmaceuticals, Inc. 55
CureFAKtor Pharmaceuticals. LLC 56
Kancera AB 57
Netris Pharma S.A.S. 58
Neuroblastoma - Therapeutics Assessment 59
Assessment by Monotherapy Products 59
Assessment by Combination Products 60
Assessment by Target 61
Assessment by Mechanism of Action 65
Assessment by Route of Administration 70
Assessment by Molecule Type 72
Drug Profiles 75
dinutuximab - Drug Profile 75
APN-311 - Drug Profile 77
APN-301 - Drug Profile 79
iobenguane I 131 - Drug Profile 81
edotreotide Labeled Yttrium 90 - Drug Profile 83
3F8-Mab - Drug Profile 85
ARC-100 - Drug Profile 87
pazopanib hydrochloride - Drug Profile 89
dasatinib + sirolimus + [irinotecan hydrochloride] + [temozolomide] - Drug Profile 93
Lutetium-177 Dotatate - Drug Profile 94
perifosine - Drug Profile 95
paclitaxel albumin-bound - Drug Profile 99
New Castle Disease Virus - HUJ Oncolytic Virus - Drug Profile 101
Natural Killer Cell Product for Adoptive Cell-Mediated Therapy - Drug Profile 102
Neuroblastoma Vaccine - Drug Profile 104
perifosine - Drug Profile 106
firtecan pegol - Drug Profile 110
NTX-010 - Drug Profile 112
irinotecan sucrosofate liposomal - Drug Profile 114
X-396 - Drug Profile 117
HU14.18K322A - Drug Profile 118
recombinant interferon gamma - Drug Profile 119
14g2a Antibody CTLs - Drug Profile 120
LEE-011 - Drug Profile 121
Dendritic Cell Vaccine + [decitabine] + [imiquimod] - Drug Profile 123
Tri-Virus Specific Cytotoxic T-cells - Drug Profile 124
Peptide Cocktail Vaccine - Drug Profile 126
fenretinide - Drug Profile 127
eflornithine hydrochloride - Drug Profile 129
hu3F8-BsAb - Drug Profile 130
BACPT DP - Drug Profile 131
CEP-28122 - Drug Profile 132
Chk-1 Inhibitor Programme - Drug Profile 133
CBL-0137 - Drug Profile 135
TH-302 - Drug Profile 136
TRBS-07 - Drug Profile 143
JW-1521 - Drug Profile 144
CFAK-C4 - Drug Profile 145
Drug Targeting Netrin-1 - Drug Profile 147
1-B7 - Drug Profile 148
BL-8040 - Drug Profile 149
crizotinib + Torin-2 - Drug Profile 151
BXQ-350 - Drug Profile 152
BN-210 - Drug Profile 154
cVE-199 - Drug Profile 155
Nerofe - Drug Profile 156
CCT-244747 - Drug Profile 157
MYCN-DNA Vaccine - Drug Profile 158
MCT-1 Inhibitors - Drug Profile 159
RKS-262 - Drug Profile 161
Bromoacetoxycalcidol - Drug Profile 163
Peptide to Inhibit Src Tyrosine Kinase for Oncology - Drug Profile 164
AMXT-1501 + eflornithine - Drug Profile 165
Macrovax Vaccine - Drug Profile 167
TR-100 - Drug Profile 168
FSEC Peptide - Drug Profile 169
Anti Tropomyosins For Cancer - Drug Profile 170
M-606 - Drug Profile 171
Small Molecules to Inhibit Aurora Kinase and ALK Kinase for Oncology - Drug Profile 172
HC Toxin - Drug Profile 173
BMP-4 - Drug Profile 174
Fe-SP - Drug Profile 175
Small Molecules for Oncology and Infectious Disease - Drug Profile 177
12-a - Drug Profile 178
ALK Fusion Proteins Inhibitors - Drug Profile 179
Pancratistatin Derivatives - Drug Profile 180
Small Molecule for Neuroblastoma - Drug Profile 181
Syrbactins - Drug Profile 182
Drugs To Inhibit HDAC For Multiple Myeloma and Neuroblastoma - Drug Profile 183
Bispecific Antibodies to Target CD3 for Neuroblastoma - Drug Profile 184
Bispecific Antibodies to Target GD2 for Neuroblastoma - Drug Profile 185
CFAKY-15 - Drug Profile 186
LB-102 - Drug Profile 187
Neuroblastoma - Recent Pipeline Updates 188
Neuroblastoma - Dormant Projects 219
Neuroblastoma - Discontinued Products 220
Neuroblastoma - Product Development Milestones 221
Featured News & Press Releases 221
Appendix 229
Methodology 229
Coverage 229
Secondary Research 229
Primary Research 229
Expert Panel Validation 229
Contact Us 230
Disclaimer 230

List of Table

List of Tables
Number of Products under Development for Neuroblastoma, H1 2014 15
Number of Products under Development for Neuroblastoma - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 18
Number of Products under Development by Companies, H1 2014 (Contd..1) 19
Number of Products under Development by Companies, H1 2014 (Contd..2) 20
Number of Products under Investigation by Universities/Institutes, H1 2014 22
Number of Products under Investigation by Universities/Institutes, H1 2014 (Contd..1) 23
Comparative Analysis by Late Stage Development, H1 2014 24
Comparative Analysis by Clinical Stage Development, H1 2014 25
Comparative Analysis by Early Stage Development, H1 2014 26
Comparative Analysis by Unknown Stage Development, H1 2014 27
Products under Development by Companies, H1 2014 28
Products under Development by Companies, H1 2014 (Contd..1) 29
Products under Development by Companies, H1 2014 (Contd..2) 30
Products under Investigation by Universities/Institutes, H1 2014 31
Neuroblastoma - Pipeline by United Therapeutics Corporation, H1 2014 32
Neuroblastoma - Pipeline by Shionogi & Co., Ltd., H1 2014 33
Neuroblastoma - Pipeline by GlaxoSmithKline plc, H1 2014 34
Neuroblastoma - Pipeline by Gamida Cell Ltd., H1 2014 35
Neuroblastoma - Pipeline by BioLineRx, Ltd., H1 2014 36
Neuroblastoma - Pipeline by Novartis AG, H1 2014 37
Neuroblastoma - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2014 38
Neuroblastoma - Pipeline by Teva Pharmaceutical Industries Limited, H1 2014 39
Neuroblastoma - Pipeline by Progenics Pharmaceuticals, Inc., H1 2014 40
Neuroblastoma - Pipeline by Celgene Corporation, H1 2014 41
Neuroblastoma - Pipeline by AEterna Zentaris Inc., H1 2014 42
Neuroblastoma - Pipeline by Lixte Biotechnology Holdings, Inc., H1 2014 43
Neuroblastoma - Pipeline by Lorus Therapeutics Inc., H1 2014 44
Neuroblastoma - Pipeline by Novogen Limited, H1 2014 45
Neuroblastoma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 46
Neuroblastoma - Pipeline by Sareum Holdings plc, H1 2014 47
Neuroblastoma - Pipeline by MabVax Therapeutics, Inc., H1 2014 48
Neuroblastoma - Pipeline by Bionucleon Srl, H1 2014 49
Neuroblastoma - Pipeline by CerRx, Inc., H1 2014 50
Neuroblastoma - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2014 51
Neuroblastoma - Pipeline by Neotropix, Inc., H1 2014 52
Neuroblastoma - Pipeline by APEIRON Biologics AG, H1 2014 53
Neuroblastoma - Pipeline by Xcovery, Inc., H1 2014 54
Neuroblastoma - Pipeline by Sutro Biopharma, Inc., H1 2014 55
Neuroblastoma - Pipeline by Incuron, LLC, H1 2014 56
Neuroblastoma - Pipeline by Errant Gene Therapeutics, LLC, H1 2014 57
Neuroblastoma - Pipeline by DEKK-TEC, Inc., H1 2014 58
Neuroblastoma - Pipeline by Bexion Pharmaceuticals, LLC., H1 2014 59
Neuroblastoma - Pipeline by Cancer Prevention Pharmaceuticals, Inc., H1 2014 60
Neuroblastoma - Pipeline by CureFAKtor Pharmaceuticals. LLC, H1 2014 61
Neuroblastoma - Pipeline by Kancera AB, H1 2014 62
Neuroblastoma - Pipeline by Netris Pharma S.A.S., H1 2014 63
Assessment by Monotherapy Products, H1 2014 64
Assessment by Combination Products, H1 2014 65
Number of Products by Stage and Target, H1 2014 68
Number of Products by Stage and Mechanism of Action, H1 2014 72
Number of Products by Stage and Route of Administration, H1 2014 76
Number of Products by Stage and Molecule Type, H1 2014 79
Neuroblastoma Therapeutics - Recent Pipeline Updates, H1 2014 193
Neuroblastoma - Dormant Projects, H1 2014 224
Neuroblastoma - Discontinued Products, H1 2014 225

List of Chart

List of Figures
Number of Products under Development for Neuroblastoma, H1 2014 15
Number of Products under Development for Neuroblastoma - Comparative Analysis, H1 2014 16
Number of Products under Development by Companies, H1 2014 17
Number of Products under Investigation by Universities/Institutes, H1 2014 21
Comparative Analysis by Clinical Stage Development, H1 2014 25
Comparative Analysis by Early Stage Products, H1 2014 26
Assessment by Monotherapy Products, H1 2014 64
Assessment by Combination Products, H1 2014 65
Number of Products by Top 10 Target, H1 2014 66
Number of Products by Stage and Top 10 Target, H1 2014 67
Number of Products by Top 10 Mechanism of Action, H1 2014 70
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 71
Number of Products by Top 10 Route of Administration, H1 2014 75
Number of Products by Stage and Top 10 Route of Administration, H1 2014 76
Number of Products by Top 10 Molecule Type, H1 2014 77
Number of Products by Stage and Top 10 Molecule Type, H1 2014 78

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *